Concise Review: Human Pluripotent Stem Cells to Produce Cell‐Based Cancer Immunotherapy | Zendy

Zhu Huang | Zendy; Lai YiShin | Zendy; Li Ye | Zendy; Blum Robert H. | Zendy; Kaufman Dan S. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Concise Review: Human Pluripotent Stem Cells to Produce Cell‐Based Cancer Immunotherapy

Author(s) -

Zhu Huang,

Lai YiShin,

Li Ye,

Blum Robert H.,

Kaufman Dan S.

Publication year - 2018

Publication title -

stem cells

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.159

H-Index - 229

eISSN - 1549-4918

pISSN - 1066-5099

DOI - 10.1002/stem.2754

Subject(s) - biology , induced pluripotent stem cell , cytotoxic t cell , cancer immunotherapy , immune system , immunotherapy , adoptive immunotherapy , adoptive cell transfer , immunology , cancer research , stem cell , lymphokine activated killer cell , microbiology and biotechnology , interleukin 21 , t cell , in vitro , embryonic stem cell , gene , genetics

Human pluripotent stem cells (PSCs) provide a promising resource to produce immune cells for adoptive cellular immunotherapy to better treat and potentially cure otherwise lethal cancers. Cytotoxic T cells and natural killer (NK) cells can now be routinely produced from human PSCs. These PSC‐derived lymphocytes have phenotype and function similar to primary lymphocytes isolated from peripheral blood. PSC‐derived T and NK cells have advantages compared with primary immune cells, as they can be precisely engineered to introduce improved anti‐tumor activity and produced in essentially unlimited numbers. S tem C ells 2018;36:134–145

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research